Drug Profile
Research programme: poliovirus vaccines - Batavia Biosciences
Latest Information Update: 08 Apr 2024
Price :
$50
*
At a glance
- Originator Batavia Biosciences
- Developer Batavia Biosciences; PATH
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Poliomyelitis
Most Recent Events
- 03 Apr 2024 PATH and Bio Farma plans a phase I/II trial for Poliomyelitis (In neonates, In infants, In children, In adolescents, In adults, Prevention ) in Bangladesh (PO) in March 2025 (NCT06137664)
- 28 Feb 2022 No recent reports of development identified for research development in Poliomyelitis(Prevention) in Netherlands (PO)
- 07 Feb 2019 Univercells and consortium partners Batavia Biosciences and Merck receives grant extension from Bill & Melinda Gates Foundation for the development of poliovirus vaccines